Whether you’re thinking about the sticky film on your teeth or the buildup inside your arteries, “dissolving” plaque isn’t quite how it works in either case. Dental plaque can be physically disrupted and removed daily. Arterial plaque is more complex: it can be partially reduced and stabilized with the right combination of medication, diet, and lifestyle changes, but no pill or supplement will melt it away. Here’s what actually works for both types.
Dental Plaque: Daily Disruption Is the Goal
Dental plaque is a biofilm, a living colony of bacteria that forms continuously on your teeth. You can’t permanently dissolve it because it starts reforming within hours of being removed. The real strategy is consistent mechanical disruption: brushing and cleaning between your teeth, every day, before it hardens into tartar (calculus). Once plaque calcifies into tartar, no amount of brushing will remove it. That requires professional cleaning at a dentist’s office.
Brushing with a fluoride toothpaste that contains plaque-control agents is the foundation. But brushing alone misses surfaces between teeth, which is why interdental cleaning with floss or small brushes matters. Studies consistently show that people’s plaque levels creep back to baseline when they skip interdental cleaning or rush through their routine.
Anti-plaque mouth rinses offer a meaningful boost. A systematic review in the Journal of Clinical Periodontology found that mouth rinses were the most clinically effective delivery method for chemical plaque-control agents, producing significant improvements in gum bleeding, inflammation, and plaque levels. They work best as a supplement to brushing, not a replacement for it.
What Arterial Plaque Actually Is
Arterial plaque is a buildup of cholesterol, fat, calcium, and cellular debris inside blood vessel walls. It develops over decades and comes in different forms. Soft plaque contains a large core of fatty material covered by a thin fibrous cap. Hard plaque is more heavily calcified. The distinction matters because soft plaque, particularly the type called thin-cap fibroatheroma, is the most dangerous. Postmortem studies show that plaques associated with heart attacks and sudden death typically have less fibrous tissue, a thinner cap, and a larger fatty core than stable plaques. When that thin cap ruptures, it triggers a blood clot that can block the artery.
Stable, calcified plaque is less likely to rupture. So the medical goal isn’t necessarily to eliminate every trace of plaque. It’s to shrink the dangerous soft plaque, thicken the protective cap, and prevent new buildup. That combination is what cardiologists mean by “plaque regression” and “plaque stabilization.”
Statins: The Strongest Evidence for Shrinking Plaque
Statins remain the most proven tool for reducing arterial plaque. They work by cutting cholesterol production in the liver and increasing the number of receptors that pull LDL cholesterol out of the bloodstream. But their benefit goes beyond just lowering a number on your lab work. Statins have been shown to decrease high-risk plaque features and enhance plaque stability, essentially converting dangerous soft plaque into the more harmless, stable kind.
The clinical data on actual plaque shrinkage is specific. In the REVERSAL trial, high-dose statin therapy reduced total plaque volume by 0.4% over 18 months, while a lower-dose statin allowed plaque to grow by 2.7%. The SATURN trial pushed results further: high-dose rosuvastatin shrank total plaque volume by 4.8% over 24 months. These percentages sound small, but they represent a meaningful reversal of a process most people assume only moves in one direction.
The key factor is how aggressively LDL cholesterol is lowered. The trials showing the most regression used high-intensity statin therapy to push LDL levels well below conventional targets.
PCSK9 Inhibitors and Add-On Therapies
For people who can’t tolerate statins or whose cholesterol stays stubbornly high, PCSK9 inhibitors offer a different mechanism. These drugs block a protein that normally destroys LDL receptors on liver cells, keeping more receptors active and pulling more cholesterol from the blood. The effect on LDL levels is dramatic.
Their effect on plaque composition is less clear-cut. The GLAGOV trial found that adding a PCSK9 inhibitor for 76 weeks on top of statin therapy did not significantly change plaque composition in patients already taking statins. That doesn’t mean they’re useless for plaque. They do reduce cardiovascular events, likely by preventing new plaque from forming and reducing the raw material (LDL) that feeds existing deposits.
Low-dose colchicine, an old anti-inflammatory drug, has shown promise as an add-on to statin therapy. In two large trials (COLCOT and LoDoCo2), it reduced major cardiovascular events by 23% to 31% beyond what statins achieved alone. LoDoCo2 specifically showed that colchicine lowered the combined risk of cardiovascular death, heart attack, stroke, and the need for artery-opening procedures by 31% compared to placebo. A smaller trial of 128 patients suggests colchicine promotes plaque stabilization, likely by cooling the inflammation that makes plaques vulnerable to rupture.
How Diet Affects Plaque Progression
Diet won’t dissolve existing plaque on its own, but it can slow or stop its growth. The strongest evidence belongs to the Mediterranean diet, which is rich in extra-virgin olive oil, vegetables, fish, nuts, and whole grains. In the CORDIOPREV trial, a seven-year study of people with coronary heart disease, the Mediterranean diet decreased carotid artery wall thickness (a direct marker of atherosclerosis) while a standard low-fat diet did not change it at all. The Mediterranean diet group also showed reduced plaque height over the follow-up period.
This is a meaningful finding because it tested the Mediterranean diet head-to-head against a low-fat diet, which is what many people default to when trying to eat “heart healthy.” The low-fat diet didn’t move the needle. The olive oil-rich Mediterranean pattern did.
Supplements and Chelation: What Doesn’t Work
Vitamin K2 is widely marketed online as a way to reverse arterial calcification, based on its role in calcium metabolism. The clinical evidence doesn’t support this. A randomized, double-blinded trial published in Circulation gave patients with significant aortic valve calcification two years of vitamin K2 (MK-7) plus vitamin D supplementation. The result: no difference in calcification progression compared to placebo. Calcification scores increased by similar amounts in both groups.
Chelation therapy, which involves intravenous infusions of EDTA to remove heavy metals from the blood, has been promoted as a way to clear plaque from arteries. The NIH-funded TACT2 trial, the most recent and rigorous test of this idea, found that chelation therapy did not reduce the occurrence of major cardiovascular events in patients with diabetes who had already suffered a heart attack. These findings did not reproduce the modestly positive results from an earlier trial, and the National Institute of Environmental Health Sciences concluded that the data do not support chelation for reducing cardiovascular risk.
How Plaque Changes Are Measured
If you’re working to reduce plaque, it helps to understand how progress is tracked. Two main imaging tools exist, and they measure different things. A coronary artery calcium (CAC) score uses a CT scan to quantify hard, calcified plaque. It’s useful as a risk assessment tool, but it misses soft plaque entirely, which means a zero score doesn’t guarantee clean arteries, and a rising score after starting statin therapy doesn’t necessarily mean things are getting worse. Statins can actually increase calcification as they stabilize soft plaque into harder, safer deposits.
CT coronary angiography provides a more complete picture. It visualizes the full composite of atherosclerosis, including soft plaque, and can identify blockages. For people actively managing plaque, angiography gives a clearer view of whether treatment is working. Your cardiologist will choose the right test based on whether the goal is initial risk screening or monitoring known disease.